ストックスクリーナーアプリを入手
4.62
0.22%
-0.010
前日終値:
$4.63
開ける：
$4.7
24時間の取引高:
582.15K
Relative Volume:
1.04
時価総額：
$150.54M
収益：
$2.00M
当期純損益:
$-51.04M
株価収益率:
-2.9259
EPS:
-1.579
ネットキャッシュフロー:
$-45.65M
1週間 パフォーマンス:
-4.94%
1か月 パフォーマンス:
-24.63%
6か月 パフォーマンス:
-35.29%
1年 パフォーマンス:
+14.64%
1日の値動き範囲:
$4.54
$4.875
1週間の範囲:
$4.54
$5.03
52週間の値動き範囲:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
名前
Sagimet Biosciences Inc
セクター
電話
(650) 561-8600
住所
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
4.62 | 150.87M | 2.00M | -51.04M | -45.65M | -1.579 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-03 | 開始されました | Guggenheim | Buy |
| 2026-01-28 | 開始されました | Barclays | Equal Weight |
| 2025-08-11 | 開始されました | Wedbush | Outperform |
| 2025-08-07 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-24 | 開始されました | Canaccord Genuity | Buy |
| 2024-12-06 | 開始されました | Oppenheimer | Outperform |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-06-28 | ダウングレード | Goldman | Buy → Neutral |
| 2024-05-02 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-25 | 開始されました | Leerink Partners | Outperform |
| 2023-08-08 | 開始されました | Goldman | Buy |
| 2023-08-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-08-08 | 開始されました | Piper Sandler | Overweight |
| 2023-08-08 | 開始されました | TD Cowen | Outperform |
すべてを表示
Sagimet Biosciences Inc (SGMT) 最新ニュース
Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results - Insider Monkey
Top 10 Stocks Under $5 That Could Triple - Insider Monkey
Aug Rallies: How does Sagimet Biosciences Inc score in quality rankingsRisk Management & Consistent Growth Stock Picks - baoquankhu1.vn
Sagimet Biosciences (SGMT) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Sagimet Biosciences Stock Soars After Positive Data For Experimental Drug In Acne Study - MSN
If You Invested $1,000 in Sagimet Biosciences Inc. (SGMT) - Stock Titan
Sagimet rises after denifanstat succeeds in late stage trial - MSN
Total debt per share of Sagimet Biosciences Inc. Class A – DUS:0O2 - TradingView
HC Wainwright Has Negative Outlook for SGMT FY2027 Earnings - MarketBeat
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Sagimet Biosciences, Inc. Class A (SGMT) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Sagimet Biosciences (NASDAQ:SGMT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Q1 Earnings Forecast for SGMT Issued By HC Wainwright - MarketBeat
Citizens reiterates Sagimet Biosciences stock rating on MASH progress - Investing.com UK
Citizens reiterates Sagimet Biosciences stock rating on MASH progress By Investing.com - Investing.com Nigeria
Sagimet: Advancing FASN Inhibitor Pipeline and Solid Cash Position Support Buy Rating and $26 Target - TipRanks
Sagimet: Underappreciated, De-Risked Pipeline with Near-Term Milestones Supports Buy Rating - TipRanks
Sagimet Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sagimet Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Oppenheimer reiterates Sagimet stock rating on MASH trial progress By Investing.com - Investing.com India
Oppenheimer reiterates Sagimet stock rating on MASH trial progress - Investing.com
Sagimet Biosciences Reports 2025 Financial Results, Advances MASH and Acne Clinical Programs with Denifanstat and Resmetirom Combination 14 - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Receives Buy Rating from HC Wainwright - MarketBeat
Sagimet: Undervalued MASH and Acne Pipeline with Best-in-Class Combination Potential Supports Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Pipeline with Positive Phase 3 Results for Denifanstat in Acne and MASH Clinical Trials - Minichart
Sagimet Biosciences (NASDAQ:SGMT) Posts Quarterly Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
Sagimet Biosciences Reports 2025 Results, Highlights Clinical Progress - TipRanks
MASH and acne trial gains highlight Sagimet (NASDAQ: SGMT) 2025 update - Stock Titan
Sagimet Biosciences Q4 net loss narrows as R&D expenses fall - TradingView
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates - The Manila Times
SGMT: Positive clinical progress in MASH and acne, with $113.1M cash and $51.0M net loss in 2025 - TradingView
Sagimet 10-K: Net Loss $51.0M, EPS $(1.58) - TradingView
Acne drug filing in China, new liver trial planned by Sagimet - Stock Titan
Sagimet Biosciences Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday - MarketBeat
Sagimet Biosciences Highlights Denifanstat MASH Data, Combo Plans at Oppenheimer Healthcare Conf. - Defense World
Bull Bear: How does Sagimet Biosciences Inc score in quality rankings2025 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
SGMT Should I Buy - Intellectia AI
SGMT: Lead FASN inhibitor advances in MASH and acne, with pivotal trials and regulatory milestones ahead - TradingView
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences - The Manila Times
Sagimet Biosciences to Participate in Upcoming Investor Conferences in March 2026 - Quiver Quantitative
Biotech Sagimet lines up three March investor conferences - Stock Titan
SGMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
SGMTSagimet Biosciences Inc. Latest Stock News & Market Updates - Stock Titan
Sagimet (NASDAQ: SGMT) CMO receives 88,000-share option and 44,000 RSUs - Stock Titan
Sagimet Biosciences (SGMT) CFO awarded 88,000 options and 44,000 RSUs - Stock Titan
What is the long term forecast for Sagimet Biosciences Inc. stockChart Signals & Short-Term Swing Trade Alerts - mfd.ru
Can Sagimet Biosciences Inc. continue delivering strong returnsTrade Volume Report & Smart Money Movement Alerts - mfd.ru
Sagimet (SGMT) CEO granted 256k options and 128k RSUs in Form 4 - Stock Titan
Growth Value: Is Sagimet Biosciences Inc in a consolidation phaseJuly 2025 Retail & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Sagimet Biosciences Inc (SGMT) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):